<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01762488</url>
  </required_header>
  <id_info>
    <org_study_id>35218</org_study_id>
    <nct_id>NCT01762488</nct_id>
  </id_info>
  <brief_title>Renal Denervation in Treatment Resistant Hypertension</brief_title>
  <acronym>ReSET-2</acronym>
  <official_title>Renal Denervation in Treatment Resistant Hypertension, a Double-blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henrik Vase</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regionshospitalet Silkeborg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Randers Regional Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Jutland Regional Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regional Hospital Holstebro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital Skejby</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this double-blind, randomized and sham controlled study is to investigate the
      blood pressure lowering effect of renal denervation by catheter based ablation in the renal
      arteries in patients with milder forms of treatment resistant hypertension. The effect on
      blood pressure will be evaluated by 24-hour ambulatory blood pressure measurements at
      baseline and after 3 and 6 months of follow up. Secondary endpoint evaluation comprises
      hemodynamic assessment by applanation tonometry and the cold pressor response.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in daytime systolic blood pressure (24-hour ambulatory blood pressure measurement)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood pressure (clinic and 24-hour ambulatory blood pressure measurement)</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in central blood pressure, augmentation index and pulse wave velocity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cold pressor response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in intensity of medical antihypertensive therapy</measure>
    <time_frame>1, 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure (clinic measurement)</measure>
    <time_frame>1, 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function (eGFR and electrolytes)</measure>
    <time_frame>1, 3 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Renal denervation by ablation of the renal arteries</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>By femoral access, renal angiography is performed. The patient will be sedated. In case of acceptable renal artery anatomy allowing renal ablation, the patient will be randomized in the cath. lab. If randomized to active treatment, renal artery ablation will be carried out straight away.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>By femoral access, renal angiography is performed. The patient will be sedated. In case of acceptable renal artery anatomy allowing renal ablation, the patient will be randomized in the cath. lab. If randomized to sham treatment, the procedure stops.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation of the renal arteries</intervention_name>
    <description>Catheter-based renal denervation by applying low power radiofrequency to the renal artery using the EnligHTN Catheter, introduced by femoral artery access.</description>
    <arm_group_label>Renal denervation by ablation of the renal arteries</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Renal angiography</intervention_name>
    <description>Renal angiography by femoral access</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Systolic daytime (24 hour-ambulatory blood pressure measurement) &gt; 135 mmHg and &lt; 145
             mmHg.

          -  Stable (for at least 1 month and with no planned changes for the next 6 months)
             antihypertensive therapy with at least 3 antihypertensive drugs, including a diuretic.

          -  Documented adherence to present antihypertensive therapy

        Exclusion Criteria:

          -  Pregnancy

          -  Non compliance

          -  Heart failure (NYHA Class III-IV)

          -  LV ejection fraction &lt; 50 %

          -  Renal insufficiency (eGFR&lt;30 ml/min)

          -  Unstable coronary heart disease

          -  Coronary intervention within 6 months

          -  Myocardial infarction within 6 months

          -  Claudication

          -  Orthostatic syncope within 6 months

          -  Secondary hypertension (except CKD)

          -  Significant valvular heart disease

          -  Clinically significant biochemical abnormalities (electrolytes, haemoglobin, hepatic
             function, thyroid)

          -  Second and third degree AV block

          -  Macroscopic haematuria

          -  Renal artery anatomy not suitable for renal artery ablation (Stenosis, diameter &lt; 4
             mm, length &lt; 2 cm or severe calcifications)

          -  Moderate/severe obstructive sleep apnoea (AHI &gt; 15) if CPAP treatment has not been
             attempted
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Vase, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Skejby Hospital, Dept. of Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital, Skejby</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2013</study_first_submitted>
  <study_first_submitted_qc>January 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2013</study_first_posted>
  <last_update_submitted>May 20, 2016</last_update_submitted>
  <last_update_submitted_qc>May 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital Skejby</investigator_affiliation>
    <investigator_full_name>Henrik Vase</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Treatment Resistant Hypertension</keyword>
  <keyword>Renal Denervation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

